Eli Lilly and Company (LLY)
Has Eli Lilly Stock Peaked?
Eli Lilly (LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.
Here's why Eli Lilly stock is crashing
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.
Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook
Eli Lilly (LLY) shares could remain under the microscope on Wednesday after falling sharply in trade on Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast.
Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ET Company Participants Dave Ricks - Chairman and CEO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.
Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk how to play Eli Lilly's stock right now.
Eli Lilly Stock Slumps on Lowered Sales Forecast
Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.
Eli Lilly stumbles as weight-loss drug sales less than expected
Shares in Eli Lilly and Co fell 6.4% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market for incretins – the drugs that target hormones in the gut – grew at 45% compared to the same quarter last year but the company's previous guidance had anticipated an "even faster acceleration".Click Here Combined with lower-than-expected inventory of these tirzepatide-based drugs at year-end, this led to fourth-quarter revenue coming in lower than forecast.
Eli Lilly lowers FY revenue forecast as weight loss drug sales fall short
Shares in Eli Lilly and Co (NYSE:LLY) fell 7.3% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market for incretins – the drugs that target hormones in the gut – grew at 45% compared to the same quarter last year but the company's previous guidance had anticipated an "even faster acceleration".
Eli Lilly CEO on prospect of insurance companies covering weight loss drugs
Eli Lilly CEO David Ricks discusses the potential of insurance companies covering weight loss drugs saying they will “recognize it's the ultimate prevention medication.”
Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%
Eli Lilly saw its shares crash in early trade on Tuesday as the pharm major provided its revenue outlook for 2024 and 2025. The pharma major cut its revenue guidance for the year leading to an around 8% dip in its shares.
Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.
It was the second consecutive miss for the two closely watched obesity and Type 2 diabetes drugs.
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
